April 9, 2025- B. Braun Medical Inc. (B. Braun) announced that the U.S. Food and Drug Administration (FDA) has approved Piperacillin and Tazobactam, one of the most utilized injectable antibiotics in the U.S., for use in the Company’s DUPLEX® Drug Delivery System and will begin moving toward a full launch.
Piperacillin and Tazobactam in the DUPLEX Drug Delivery System is a ready-to-activate, two-compartment container that keeps pre-measured medication and diluent separate until the provider is ready to administer at the bedside by simply folding, squeezing and shaking to reconstitute. This system reduces overall process time by nearly four minutes per dose and shows substantial labor time savings compared to both the Baxter Mini-Bag Plus Container System and traditional compounding, offering healthcare professionals a new and efficient way to administer this critical antibiotic combination.
Continue Reading